<SEC-DOCUMENT>0001104659-12-001279.txt : 20120110
<SEC-HEADER>0001104659-12-001279.hdr.sgml : 20120110
<ACCEPTANCE-DATETIME>20120110090128
ACCESSION NUMBER:		0001104659-12-001279
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120109
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120110
DATE AS OF CHANGE:		20120110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORTHOFIX INTERNATIONAL N V
		CENTRAL INDEX KEY:			0000884624
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19961
		FILM NUMBER:		12518804

	BUSINESS ADDRESS:	
		STREET 1:		7 ABRAHAM DE VEERSTRAAT
		STREET 2:		CURACAO
		CITY:			NETHERLANDS ANTILLES
		STATE:			P8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a12-2462_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, DC 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM 8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):<b> January 9, 2012</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">
<hr size="1" width="25%" noshade color="black" align="center">
</font></b></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Orthofix International N.V.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of Registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Curacao</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.86%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-19961</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.86%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">N/A</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction of incorporation)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.86%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number) </font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.86%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7 Abraham de Veerstraat</font></b><font size="2" style="font-size:10.0pt;"><br>    <b>Curacao</b></font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="bottom" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">N/A</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices) </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code: <b>011-59-99-465-8525</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt .25in;padding:0in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105546\12-2462-1\task5036837\2462-1-ba.htm',USER='105546',CD='Jan 10 10:39 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.01.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Entry into a Material Definitive Agreement</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Amendment No. 2 to Matrix Commercialization Collaboration Agreement with Musculoskeletal Transplant Foundation</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Orthofix International N.V. (the &#147;<u>Company</u>&#148;) is party, through its wholly owned subsidiary, Orthofix Holdings, Inc. (&#147;<u>Orthofix</u>&#148;), to a Matrix Commercialization Collaboration Agreement, dated as of July 24, 2008, between Orthofix and Musculoskeletal Transplant Foundation (&#147;MTF&#148;), as amended by Amendment No. 1 thereto dated December 15, 2010 (as amended, the &#147;<u>Existing Agreement</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the Existing Agreement, Orthofix and MTF agreed to commercialize Trinity</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Evolution</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#153;</font><font size="2" style="font-size:10.0pt;">, a stem cell-based bone growth biologic matrix.&#160; Orthofix maintains exclusive marketing rights to Trinity</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Evolution</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#153;</font><font size="2" style="font-size:10.0pt;">, and MTF supplies the product, in an allograft tissue form, to customers in accordance with orders received directly from Orthofix.&#160; MTF sources, processes and packages the tissue form and is the sole supplier of Trinity</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Evolution</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#153;</font><font size="2" style="font-size:10.0pt;">&#160;to Orthofix&#146;s customers.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On January 9, 2012, Orthofix and MTF entered into Amendment No. 2 to Matrix Commercialization Collaboration Agreement (the &#147;<u>Amendment</u>&#148;).&#160; The Amendment amends the term of the Existing Agreement until the later of (i) 15 years after the date that that certain development milestones were achieved under the Existing Agreement (which occurred during 2010) or (ii) the date that certain licensing arrangements between the Company and NuVasive, Inc. expire.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the Amendment, Orthofix and MTF have agreed to collaborate to develop and commercialize a next generation of the stem cell-based bone growth biologic matrix currently sold and marketed as Trinity</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Evolution</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#153;</font><font size="2" style="font-size:10.0pt;">&#160;(the &#147;<u>Matrix II</u>&#148;).&#160; The Amendment provides that MTF will develop and improve the Matrix II, and that Orthofix will provide funding support to MTF in connection with this development.&#160; In addition, Orthofix will develop application tools and instruments in connection with the Matrix II.&#160; The Amendment also provides that the parties will share responsibility for contributing scientific or medical personnel, technical expertise and other resources to the development and improvement of the Matrix II, communicating findings and discoveries to one another with respect to the Matrix II and exchanging information related to such collaboration.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Amendment provides that, upon commercialization of the Matrix II, Orthofix will be provided with exclusive marketing rights to the Matrix II, and MTF will supply the Matrix II to Orthofix&#146;s customers in accordance with orders received directly from Orthofix, as is currently the case with the current generation of the Trinity</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Evolution</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#153;</font><font size="2" style="font-size:10.0pt;">&#160;product.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2.02.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Results of Operations and Financial Condition</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On January 10, 2012, the Company issued a press release announcing, among other things, its preliminary unaudited net sales for the fiscal quarter and year ended December 31, 2011. A copy of the press release is furnished herewith as Exhibit 99.1 and attached hereto.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_103439_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105546\12-2462-1\task5036837\2462-1-ba.htm',USER='105546',CD='Jan 10 10:39 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements and Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Exhibits</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Press release, dated January 10, 2012.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_103448_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105546\12-2462-1\task5036837\2462-1-ba.htm',USER='105546',CD='Jan 10 10:39 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="52%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:52.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Orthofix International N.V.</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Brian McCollum</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:44.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Brian   McCollum</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer and Senior Vice President of Finance</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: January 10, 2012</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_103632_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105546\12-2462-1\task5036837\2462-1-ba.htm',USER='105546',CD='Jan 10 10:39 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT INDEX</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="9%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.72%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:9.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press   release, dated January 10, 2012.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_103705_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\105546\12-2462-1\task5036837\2462-1-ba.htm',USER='105546',CD='Jan 10 10:39 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a12-2462_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="408" height="63" src="g24621mmi001.jpg" alt="GRAPHIC"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Orthofix International Announces Preliminary Fourth Quarter Sales and New Development Agreement with MTF</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LEWISVILLE, Texas - January 10, 2012 (BUSINESS WIRE) &#151; Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today preliminary unaudited fourth quarter net sales are expected to be a record of approximately $151.3 million, increasing 5% over $143.8 million in the fourth quarter of the prior year. For the full year 2011, net sales are anticipated to be approximately $578.7 million.&#160; President and Chief Executive Officer Robert Vaters said, &#147;I am very pleased with our preliminary net sales results, which represent the second consecutive quarter of record sales. I remain confident in our ability to grow faster than the overall markets where we participate.&#148; The Company will be reporting final 2011 financial results along with 2012 guidance next month.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, the Company announced that it has reached an agreement with MTF to both co-develop and commercialize a new technology for use in bone grafting applications and to expand MTF&#146;s Trinity Evolution processing capacity.&#160; MTF and Orthofix have also extended the initial term of their existing agreement for an additional five years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Our collaboration with Orthofix has been highly successful, and we are excited to expand our partnership through the development of this innovative new tissue form for the benefit of surgeons and patients,&#148; said Bruce Stroever, Chief Executive Officer of MTF.&#160; The new tissue form incorporates all three properties necessary to facilitate bone growth, enables excellent handling characteristics, and is complementary to Trinity Evolution.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mr. Vaters added, &#147;Together with the expanded capacity for Trinity Evolution, we are adding to our biologic pipeline and are very well positioned to help MTF fulfill its mission and meet the market&#146;s increased demand for novel bone grafting solutions.&#148;&#160; The parties plan to introduce the new tissue form in 2013.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Orthofix</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative repair and regenerative technologies to the spine and orthopedic markets. Orthofix&#146;s products are widely distributed around the world to orthopedic surgeons and patients via Orthofix&#146;s sales representatives and its subsidiaries,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105546\12-2462-1\task5036837\2462-1-mm.htm',USER='105546',CD='Jan 10 10:43 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">including BREG, Inc., and via collaborations with other leading orthopedic product companies.&#160; In addition, Orthofix is collaborating on R&amp;D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, Texas Scottish Rite Hospital for Children, and the Cleveland Clinical Foundation.&#160; For more information about Orthofix, please visithttp://www.orthofix.com/ www.orthofix.com.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About the Musculoskeletal Transplant Foundation</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Musculoskeletal Transplant Foundation is the nation&#146;s largest full service tissue organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. A not-for-profit organization, MTF is a consortium of academic medical institutions and organ and tissue recovery organizations across the country. In its first 20 years, MTF and its recovery partners have recovered over 60,000 donors and provided over 3 million tissue grafts to patients in need. For more information, please visit MTF&#146;s website at www.mtf.org.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995.&#160; These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries and are based on management&#146;s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The forward-looking statements in this release do not constitute guarantees or promises of future performance.&#160; Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the expected sales of our products, including recently launched products, unanticipated expenditures, the resolution of pending litigation matters (including the government investigation and False Claims Act matters relating to our bone growth stimulation and spinal implant businesses, and the possible violations of the FCPA by our former Mexican orthopedic distribution entity, as well as certain product liability claims against our sports medicine global business unit), changing relationships with customers, suppliers, strategic partners and lenders, changes to and the interpretation of governmental regulations, risks relating to the protection of intellectual property, changes to the reimbursement policies of third parties, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the orthopedic industry, credit markets and the economy, corporate development and market development activities, including acquisitions or divestitures, unexpected costs or operating unit performance related to recent acquisitions, and other factors described in our annual report on Form 10-K and other periodic reports filed by the Company with the Securities and Exchange Commission (SEC).&#160; Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105546\12-2462-1\task5036837\2462-1-mm.htm',USER='105546',CD='Jan 10 10:43 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">which speak only as of the date hereof.&#160; The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances, or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company cannot predict the timing or outcome of ongoing litigation matters and governmental investigations of our businesses which could result in civil or criminal liability or findings of violations of law (as further described in the &#147;Legal Proceedings&#148; sections of our annual report on Form 10-K and quarterly reports on Form 10-Q), that could materially impact our financial position and/or liquidity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contact</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">:</font></b></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mark   Quick</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director of Investor Relations and Business   Development</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">markquick@orthofix.com</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">214-937-2924</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Source</font></u></b><font size="2" style="font-size:10.0pt;">: Orthofix International N.V.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105546\12-2462-1\task5036837\2462-1-mm.htm',USER='105546',CD='Jan 10 10:43 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g24621mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g24621mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!``9@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:HKBY@M(
M&GN9DAB099W;`%2,"5(4X/8D9K#U#PCIVKOOU22YNV'0/,55?HJX`JHJ-_>9
M,G)+W4<UK_Q0ABW6^AQ><_3[1*,(/H.I_'%>>ZAJVHZI,TM]>2SLQSAF^4?0
M=!7HU]\,M'O87?1[UX74E<%_,3(['N/SKSW6-$O]!O3:W\/EL>4<<JX]0:]C
M#.AM#?SW/%Q7UC>>WEL5(+FXM7\RWGDA?^]&Y4_I77^'_B3J6GR+%JA-];="
MQ_UJ^^>_X_G7&45TSIPJ*TD<M.K.F[Q9]#6&H6NJ64=Y9S++#(,JP_D?0U9K
MQ;P1XG?P_JJPS.?L%RP653T0]G']?:O:`01D'(->)B*+I2MT/>P]=5H7ZBT4
M4A.!DUSG0+17.:I\0?">CR-'>:Y;"1>L<1,C#ZA<XK%;XT^"P<"[N6]Q;-0!
MWM%<-;_&+P5.X4ZC+#[R6[@?H#73Z5XAT;7$WZ7J=M=XZB*0%A]1U%`&E111
M0`45F:GXDT313C4]5M+5O[LLH#?EUK%;XI>"58@Z_#D>D<A_]EH`ZVBN2'Q2
M\$L0!K\//K'(/_9:VM+\2:)K7&F:K:7;?W8I06'X=:`-.BLC7?%6B>&O)_MB
M_2T\_/E[E8[L8ST!]163_P`+3\$?]!^+_OU)_P#$T`=;17)?\+3\$?\`0?B_
M[]2?_$T?\+3\$?\`0?B_[]2?_$T`=;17)?\`"T_!'_0?B_[]2?\`Q-7=(\=^
M&->OUL-+U:.YN7!98U1P2`,GJ`*`.@HKE)/BAX*BD:-]>B#(2K#RI."/^`UN
M:/K6G:_8"^TNZ6YMBQ42*I`R.HY`H`OT45FZWXATGPY:I<ZO>+:0R/L5F5CE
ML$XX![`T`:5%<O:_$GP?>W<-I;:W%)-.XCC01R#<Q.`.5]:ZB@`HK/U77M(T
M.,2:IJ5M:`]!+(`3]!U-<O<_&+P5;OM&I23>\5NY'Z@4`=Q17!#XT^"R<&[N
M1[FV:MC3/B)X2U9UCM=<MA(W1)28B?\`OK&:`.EHI`0P!!!!Y!%+0`45#=7E
MK8PF:[N8K>(=7E<*/S-<]<?$CP;;,5D\0VA(_P">9+_^@@T`=/17)?\`"T_!
M'_0?B_[]2?\`Q-'_``M/P1_T'XO^_4G_`,30!UM%8-KXW\-WNDW>JV^JQR65
MF0)Y0C@(3TXQGOVJA_PM/P1_T'XO^_4G_P`30!UM%8FI>,?#^CV=I>7^HK!;
MWJ[X)3&Y5Q@'J!QP>AK-'Q2\$D@#7X>?6.0?^RT`=;138Y$EC62-U='`964Y
M!!Z$&G4`%%<[JGC[PKHM^]AJ&LPPW,>-\>UF*Y]<`\^U)IGC_P`+:S?1V.G:
MLEQ<29VHD4G;DG)7`'N:`.CHK+A\2:1<3I#'>`F1MD;E&$;MZ*Y&TGZ&B@"#
M7?%FD^'T(NY]\^/E@B^9S_A^->9^(/'VK:UNAA?[%:GCRXF^9A_M-_ABN9EE
M>>>2:1BSR,68GN33:]RCA84]7JSP:V,J5-%HCV/X:,#X.B`[32`_G6WKFB6F
MOZ;)97:\'E'`^:-NQ%<?\)[\/87NGLWS12"51[,,']1^M>@UY=>\*S:[GJX>
MTZ$4^Q\]ZIIMQI&I3V%TN)86P3V8=B/8BJE>G?%31EDL[?68E^>%O*E([J>A
M_`_SKS&O9H5/:P4CQ,12]E4<0(S7M7@'5FU7PM`96W36Q,#DGDXZ'\L5XK7H
M_P`)+@XU.V/3,;C]0?Z5AC8WI7[&^!GRU;=ST<D*I9B`!R2>U?.GQ&^)E_XC
MU&?3],N7M](B8HHC.#<8_B8^A[#TKVOQ[>26'@36;B(E7%JZJ1VW?+G]:^5*
M\4]TW/"O@_5_&&H&UTR$;4P99Y#B.(>Y]?8<UZ=:?L_VXA'VW7Y#)W$,`"C\
MSS76_"/2X=-^'MA)&H$EYNGE8#EB20/R`%=K0!X;K7P%O[:W>;1M5CO&49$$
MT?ELWL&R1GZXKR[-_HVI$`S65Y;.0<$H\;#^5?8=?/\`\==,AM/%]M>Q*%:]
MM@TF.[*2,_EC\J`.Y^%'Q$F\56\FE:JP.I6J;UEX'GITR1_>'&?7/UK/^+_Q
M#O-$D3P_HTQAN9(P]S<+]Z-3T5?0GKGTQ7FGPPO)++XB:0\;8\R;RF'J&!!_
MG3/B5<-<_$36G8D[;C8/HH"_TH`P[*QU#7=32UM(9;R\N&X4?,S'N23_`#->
MC6/P%UZ>%7O-2LK5CU0;I"/RP*R?ACXRT/P7/?7>I6ES/<SJJ1-"JG8O);J1
MU./RKT+_`(7SX:_Z!^I?]\)_\50!R=Y\!=?AA9[74K*Y<=(SN0M^)&*\V=;O
M2M0="9+:[MI"IVMAHW4X/([@U[9>_'W24A;[!H]W++CY?.947/O@DUXG?7DV
MIZE<7LP!FNI6D8*.-S')P/QH`]:L])U'XQ^#].FGU*.WO-*ED@GDDC+>=D*5
M;COCK[U#_P`,_P"H?]!^V_[\-_C7:_"#PY=^'O!H-]&T5Q?3&X,3#!12`%!'
M8X&?QKNZ`/EOQSX'G\#WEK;3WT=V;F,N"B%=N#CO69X8T*3Q-XBM-&BG6W>Z
M+`2,N0N%+=/PKT3X_P#_`"&](_Z]G_\`0JY3X4_\E+T?_?D_]%O0!UW_``S_
M`*A_T'[;_OPW^-=#X&^$MYX1\31:O-JT-RD<;H8TB*D[ACJ37I]%`'QYJ7_(
M4N_^N[_^A&OH/X)_\D\B_P"OF7^8KY\U+_D*7?\`UW?_`-"-=YX*^+)\'^'D
MTD:.+K;*TGF>?L^]VQM-`'T/7EWQZ_Y%*Q_Z_1_Z`U9'_#03?]"X/_`O_P"Q
MKF/'GQ//C;2(+`Z4+/R9Q+O\[?G@C&,#UH`YOP=_R.>B_P#7]#_Z&*]Q^*OQ
M!D\)646GZ8R_VG=J6#D9\E.F['J3P/H:\.\'?\CGHO\`U_0_^ABM?XKWDEY\
M1M4\P\0LL2#T`4?UR?QH`YB::^U?4-\TDUY=W#XRQ+N[$\#U->G:#\"-2O+9
M)]9U)+`N,^1&GF.OU.0`?IFL[X'Z7#?>-I+J90WV&V:6,$=')"@_@":^AJ`/
M'KK]G^V,1^R:_*LG;S;<$'\B*\T\6^"M8\&WB0ZE&K12Y\FXB.4DQ_(^QKZL
MKD/BIIL.I?#W4_-0%K9!/&3_``LI_P`,C\:`/'?A[\2M0\+7\-G?3R7&D2,%
M>-SDPY_B3TQW'0U[QXF\1VWASPS<ZW)B5(HP8E!_UC'A0#[DC\*^3*]2\::M
M/<_!?PK&[G,SX;)Y81AE']*`.!U_Q)JOB;4'O=4NWF<DE4S\D8]%'85U?AWX
M-^(]=LH[V9H-.@E4,GGY+L#T.T=/QQ7%:5<6UIJUI<WD!GMX9E>6($`NH.2.
M?6O9_P#A?^F?]`&Z_P"_R_X4`9J_L_7>/F\0P@^UL3_[-2_\,_7/_0Q1?^`I
M_P#BJT?^&@--_P"@%=?]_E_PK6\+_&&Q\3^(;;1X=(N('N"V)'E4A<*6Z?A0
M!D7_`(&D\#?"GQ+;27ZWAN?+<,L>S;AE&.IKP^OI_P"*7_)-M9_ZY)_Z&M?,
M%`'U/INBV'B#X>:=IFI0":WFL(@0>JG8,,#V(]:^?/&W@J_\%ZN;6X!EM9"3
M;7(7`D7T]F'<5](^$_\`D4='_P"O*'_T`4_Q#X>T_P`3Z1+IFI1;XGY5A]Z-
MNS*>Q%`'C?PH^)9TF6/P]K4_^@N<6T[G_4$_PD_W3^GTZ=S\3?B+%X3L#8:?
M(LFKW"97'(@4_P`9]_0?C]?#O%WA2^\'ZV^FWN'!&^&5>DJ9X/MTZ5CLT]W<
M#>[2RN0H9VR3V')_"@">TM+_`%W54M[=)+N]NY.!G+.QY))_4FOH3PW\.8_#
M'@Z]M;?9-J]Y;E9ILXW<?ZM3V7MG\:D^&WP\M_!^GB[NPDVK7"_O9!R(A_<4
M_P`SW^E=S0!Y0VFO=:W>RVZ,[WAN$ALQ&8Y;9F1%C9^.%4JQQG"D`C.:*]7H
MH`^>]5M#I^L7EF1CR)G0?0'C]*J5V_Q/T8VFM1ZI&O[J\7:Y':11_48_(UQ%
M?14I\\%(^:K0]G4<39\*:V?#^OP7C$^0W[N8#^X>_P"'!_"O=(Y$EC62-@R.
M`RL#P0>]?.5=]X"\;I8*FCZK)MM\X@G8\1_[)]O0]JY,90<USQW1V8+$*#Y)
M;,[WQ-9B_P##6H6Q&=T#$?4#(_45X(.@KZ'O&7^SYV)!3RF.0>HQ7SP.E3@'
M[LD5F*7-%A7HWPD@;.IW'\/[M![GDG^E><U[9X$T9M&\,PI,NV>X/G2`]03T
M'X#%:XV:C2MW,<#!RJW[%GQCILFK^#]5L(ANEFM7$8]6`R!^8%?)I!!P1@BO
MLRO%?B-\(KN6^FUGPU")DF8O-9+PRL>I3U!]/R]O%/=.K^#6O6^J>"(+`2#[
M3IQ,4B9YVDDJWTP<?A7?U\C6=YK?A351/;O<Z;>Q<'<I0_0@]1[&NWM/CKXH
M@B"3VMA<L/XVC92?R.*`/H*OG3XSZ_!K/C,6UK(LD6GQ>064Y!?)+?ED#\#5
M;6_B_P"+-:MWMA<Q6,+C#"U3:Q'IN))'X8KG]#\*:[XDN!'IFG3S[CS*5Q&O
MN6/`H`V/A1ILNH_$/3=@.RV9IY#Z!0<?J0/QJC\0?^1_US_K\?\`G7O/P[\`
M0>"=-<R2+<:C<X\^91P`.B+[?SKP3Q^X?Q]KA'_/[(/R.*`.D^&'P]TOQK97
M\^H7-U"UM(B((&4`@@GG(/I7<-\!?#A4A=1U$''!+(<?^.U2_9__`.05K/\`
MUWC_`/037KM`'R3XF\.7WA77)]+OU^>,Y20#Y94/1A[&O0_@K>^&);S^S[[3
M;9=84E[:ZD&XR#T&>`P]NH^E>C_$+P1;^,]#,2A8]0MP6M9CZ]U/^R?TZU\T
M21WNC:F8W$EI>VDN"/NM&ZG^>:`/L.BN)^&OC^'QCI0@NF2/5;90)X^GF#^^
MH]/7T/U%=M0!X9\?_P#D-Z1_U[/_`.A5RGPI_P"2EZ/_`+\G_HMZZOX__P#(
M<TG_`*]G_P#0JY3X4_\`)2]'_P!^3_T6]`'T]1110!\>:E_R%+O_`*[O_P"A
M&O7OAA\/?#/B3P='J&J6#37)GD0N)G7@'C@&O(=2_P"0G=_]=G_]"-?0?P3_
M`.2>1?\`7S+_`#%`%G_A3_@C_H%/_P"!,G^-<+\6O`OA[POX=M;O2+)H)I+H
M1LQE9LKM8XP3["O<:\N^/9_XI*P_Z_1_Z`U`'CO@[_D<]%_Z_H?_`$,5O?%_
M3)-/^(=[(RD1WBI/&?4%0#^H-8'@\X\9Z+G_`)_H?_0Q7T1\0/`EMXVTI8]Z
MP7]ODVTY'`SU5O\`9/Z4`>-_!W7H-$\;I'=2".&_B-ON8X`8D%<_B,?C7TA7
MR9KWA'7O#4[1ZGITT2@\3*NZ-O<,.*WM"^+OBS1+9+;[3%?0QC"K=IN8#TW`
M@_GF@#Z5KA/B_KUOI/@:ZM&D'VG4<01)GDC(+'Z`?S%><W7QV\3S1;8+33[=
MC_&L;,1^;8KA[_4=;\5ZIY]W)<ZC>/P`JEB!Z*HZ#V`H`S*]/^(>FRZ3\,?!
M]G,I61%=G4]06`8C]:N_#SX/WKWT&K>)H?(@B8/'9-R\A'3?Z#VZFM/]H#_D
M%Z,/^FTO_H*T`>2^%M/M]5\4Z9I]VK-!<W*1R!3@E2<'FO>?^%+>"_\`GUNO
M_`EJ\/\``O\`R/>A_P#7]%_Z$*^KJ`.!_P"%+>"_^?6Z_P#`EJOZ)\+_``QX
M?U:'5-/M[A+F#.PM.S#D$'CZ&NOHH`Y+XI?\DVUG_KDG_H:U\P5]/_%+_DFV
ML_\`7)/_`$8M?,%`'UKX3_Y%'1_^O*'_`-`%9WCGQS8>"M*\Z;$U[,"+:V!Y
M<^I]%'<UEW7C?3O!GP[TBXN&6:[EL(OLUL&^:0[!R?11W-?/VLZSJ/B/5I=0
MU"9I[F=OP`[*H[`=A0`[4M2U3Q1KCW=TSW5[=R`!5&<D\!5'IV`JUXF\(ZOX
M2N((=5@"?:(Q(CH<J?5<^H[BO8_A5\-1H$":YK$(.IRKF&)A_P`>RG_V8_IT
M]:[7Q3X8L/%FB2Z9?K@-\T4H'S1/V8?YY%`'EGPH^)_D&'PYKT_[H_+:74C?
M=]$8^GH>W3Z>V5\C>(O#]_X8UF;2]0CVRQ'Y6'W9%[,/8UZO\*?B>)EA\.:_
M<?O!A+2ZD/WO1&/KZ'OT^H![%1110!G:]HT&O:1-I\_`D&4?NC#H:\+U+3;K
M2+^6QO(S'-$<'T8=B/4&OH6L;Q%X8T_Q);".[4I,@_=SI]Y/\1[5V8;$>R=I
M;'%BL-[97CN>$UJZ)X:U7Q!)ML;8F+.&F?Y47\>_T%>A:+\,=.L9?.U*8W[`
M_+'MVI^([_RKM8XXX(@D:+'&@P%48"BNJKCHK2GJ<E'`2>M30XVZLY?!O@&]
MBN-2ENW>/RXP_P!U"W&%[XYSU[5Y,BL[*B*69CA549)_"O5O$.DZIXUU"*WA
M/V32+9L^?(.9G[E5[@=`3QUK=T+PGI/A]`;6#?/CYIY?F<_X?A44\1&E!N6L
MF:5,/*M-*.D4<7X-^']RUW'J6M0^5%&0T=NWWG/8L.P'I7I]%%<-6K*K*\CN
MHT8TH\L0HHHK(V(+JQL[Y-EW:PW"^DL88?K64_@GPK(Q9_#FF,Q[FU3_``K<
MHH`R+;PGX<LVW6^A:=$?5;9!_2M5$6-0B*%4<``8`IU%`!5232M.ED:233[5
MW8Y9FA4DGW.*MT4`0V]I;6@86UO%"&Y(C0+G\JFHHH`*JRZ9I\\AEFL;:21N
MK/$I)_$BK5%`%:#3K&VD\RWLK>%\8W1Q*IQ]0*LT44`07%C:7;!KFUAF*C`,
MD8;'YTR+3-/@E$L-C;1R+T9(E!'X@5:HH`****`*9T?2V))TVT)/4F!?\*L0
M6\-M'Y=O#'$F<[8U"C\A4E%`!45Q:V]T@2Y@CF4'(61`P!_&I:*`*B:3IL;J
MZ:?:JRG(985!!_*K=%%`#6574JRAE/!!&0:R[GPIX=O&W7.A:?*?5K9#_2M:
MB@##3P1X51@R^'-,!'<6J?X5J6MA9V*[;2T@MU](HPG\JL44`%0W%I;7847-
MO%,%Y`D0-C\ZFHH`J1Z5IT4BR1Z?:HZG*LL*@@_7%6Z**`"BBB@!DL4<\;13
M1K(C=5=00?P-5?[&TO\`Z!MI_P!^%_PJ[10!6ETVPGV^=96\FQ=J[XE.T>@X
MZ4Q=)TQ'#IIUJK*<@B%00?RJY10`4444`5[BQL[M@US:03,HP#)&&('XU&-'
5TL$$:;:`CD'R%_PJY10`4444`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
